Render Target: STATIC
Render Timestamp: 2025-01-21T04:09:45.636Z
Commit: da7e4f2f0d1aed1f1f8e20e4e2ecab8f33cbd595
XML generation date: 2024-11-20 17:36:08.685
Product last modified at: 2025-01-01T09:07:33.951Z
Cell Signaling Technology Logo

Basket Updated

0

Items added

1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

PD-L1 (Atezolizumab Biosimilar) Human mAb #33052

PD-L1 (Atezolizumab Biosimilar) Human mAb: Image 1
Binding kinetics of PD-L1 (Atezolizumab Biosimilar) Human mAb to recombinant PD-L1 were measured using bio-layer interferometry (BLI) on the Octet RED96 (Sartorius). Antibodies were immobilized to ProA biosensors (Sartorius), which were then dipped into wells containing a 2-fold dilution series of recombinant PD-L1. Concentrations tested ranged from 1,000 nM to 15.6 nM. Global curve-fitting was performed using a 1:1 binding model; only the concentrations that passed that fitting are shown.

To Purchase # 33052

Cat. # Size Qty. Price Ships
33052SF 100 µg
$378

Supporting Data

REACTIVITY H
SENSITIVITY Endogenous
MW (kDa)
Source/Isotype Human IgG1 kappa
Species Cross-Reactivity Key:
  • H-Human 

Product Information

Product Description

PD-L1 (Atezolizumab Biosimilar) Human mAb is a biosimlar antibody for Atezolizumab. Atezolizumab is a human monoclonal antibody directed against PD-L1 that is designed to function as an immune checkpoint inhibitor by disrupting the interaction between PD-L1 and PD-1.
Endotoxin <0.1 EU/μg of antibody

Product Usage Information

This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

Formulation

Supplied in 1X PBS, BSA and Azide Free.

Storage

Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

Specificity / Sensitivity

PD-L1 (Atezolizumab Biosimilar) Human mAb was confirmed to bind to its intended target protein PD-L1 using flow cytometry and bio-layer interferometry.

Species Reactivity:

Human

Source / Purification

PD-L1 (Atezolizumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Atezolizumab is an antibody that is directed against the extracellular region of human PD-L1.

Background

Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The PD-L1 ligand binds the PD-1 transmembrane receptor and inhibits T cell activation. PD-L1 was discovered following a search for novel B7 protein homologs and was later shown to be expressed by antigen presenting cells, activated T cells, and tissues including placenta, heart, and lung (1-3). Similar in structure to related B7 family members, PD-L1 protein contains extracellular IgV and IgC domains and a short, cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas (4-6). Expression of PD-L1 in cancer is associated with tumor-infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma (7). Additional research links PD-L1 expression to cancers associated with viral infections (8,9).
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.